Page last updated: 2024-11-12

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Sialyl Lewis X Antigen: A sialylated version of Lewis X antigen expressed on cell surfaces. It is a ligand for SELECTINS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc : A branched amino tetrasaccharide consisting of a sialyl residue, linked (2->3) to a galactosyl residue that in turn is linked (1->4) to a glucosaminyl residue, which is also carrying a fucosyl residue at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11828886
CHEBI ID61711

Synonyms (14)

Synonym
sialyl lewis x mimetic
alpha-neup5ac-(2->3)-beta-d-galp-(1->4)-[alpha-l-fucp-(1->3)]-d-glcpnac
alpha-neu5ac-(2->3)-beta-d-gal (1->4)-[alpha-l-fuc-(1->3)]-d-glcnac
sialyl lewis x antigen
CHEBI:61711 ,
alpha-n-acetylneuraminyl-(2->3)-beta-d-galactosyl-(1->4)-[alpha-l-fucosyl-(1->3)]-n-acetyl-d-glucosamine
5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-[6-deoxy-alpha-l-galactopyranosyl-(1->3)]-2-acetamido-2-deoxy-d-glucopyranose
5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-beta-d-galactopyranosyl-(1->4)-[alpha-l-fucopyranosyl-(1->3)]-2-acetamido-2-deoxy-d-glucopyranose
neuacalpha2-3galbeta1-4(fucalpha1-3)glcnac
EPITOPE ID:141586
alpha-neup5ac-(2->3)-beta-d-galp (1->4)-[alpha-l-fucp-(1->3)]-d-glcpnac
neuacalpha2->3galbeta1->4(fucalpha1->3)glcnac
NIGUVXFURDGQKZ-KRAHZTDDSA-N
Q27131306

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice."( Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Choi, SH; Stevenson, JL; Varki, A, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
amino tetrasaccharideA tetrasaccharide derivative having one or more substituted or unsubstituted amino groups in place of hydroxy groups at unspecified positions.
glucosamine oligosaccharide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Carbohydrate metabolism173120
Blood group systems biosynthesis913
Lewis blood group biosynthesis512

Research

Studies (956)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's333 (34.83)18.2507
2000's402 (42.05)29.6817
2010's178 (18.62)24.3611
2020's43 (4.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (1.00%)5.53%
Reviews70 (7.02%)6.00%
Case Studies14 (1.40%)4.05%
Observational0 (0.00%)0.25%
Other903 (90.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]